| CEO Name | Ryan Watts |
| Nationality | United States |
| Net Worth Estimation | $60 million |
Ryan Watts's estimated net worth of around $60 million stems from his role as CEO of Denali Therapeutics, equity holdings, and compensation packages linked to the company's strong performance in the biopharmaceutical industry. Additional wealth accrues from milestone-based bonuses and increased valuation as Denali advances its neurodegenerative disease pipeline.
Ryan Watts, CEO of Denali Therapeutics, has an estimated net worth of $60,000,000, which is 75% of the maximum and 600% of the minimum CEO net worth in the biotechnology sector. This positions him well above the lower benchmark and close to the industry's higher end.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Ryan Watts Performance in Denali Therapeutics
Ryan Watts, CEO of Denali Therapeutics, demonstrates strategic leadership focused on advancing neurodegenerative disease treatments. His decision-making drives innovation through strong investments in research and partnerships, accelerating pipeline development. Under his guidance, Denali Therapeutics has improved operational performance and strengthened its position in the biotech industry.
Latest News
Denali Therapeutics CEO Ryan Watts Leads Company Through Key Milestones and FDA Review Extension
Denali Therapeutics, under CEO Ryan Watts, completed its BLA submission for tividenofusp alfa for Hunter syndrome and recently faced an FDA review extension, now targeting April 2026 for approval. The company also raised $500 million in financing, spun out its small molecule pipeline, and opened a new biomanufacturing facility, positioning itself as a leader in brain disease therapeutics.
Source: http://www.statnews.com/2025/01/08/tenvie-therapeutics-denali-neuorscience-drug-candidates/